Preclinical development of a microRNA-based therapy for intervertebral disc degeneration

Nat Commun. 2018 Nov 28;9(1):5051. doi: 10.1038/s41467-018-07360-1.

Abstract

Understanding the molecular mechanisms regulating the maintenance and destruction of intervertebral disc may lead to the development of new therapies for intervertebral disc degeneration (IDD). Here we present evidence from miRNA microarray analyses of clinical data sets along with in vitro and in vivo experiments that miR-141 is a key regulator of IDD. Gain- and loss-of-function studies show that miR-141 drives IDD by inducing nucleus pulposus (NP) apoptosis. Furthermore, miR-141 KO in mice attenuated spontaneous and surgically induced IDD. Mechanistically, miR-141 promotes IDD development by targeting and depleting SIRT1, a negative regulator of NF-κB pathway. Therapeutically, upregulation or downregulation of miR-141 by nanoparticle delivery in IDD model aggravated or alleviated experimental IDD, respectively. Our findings reveal a novel mechanism by which miR-141, in part, promotes IDD progression by interacting with SIRT1/NF-κB pathway. Blockade of miR-141 in vivo may serve as a potential therapeutic approach in the treatment of IDD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Intervertebral Disc Degeneration / genetics
  • Intervertebral Disc Degeneration / metabolism*
  • Intervertebral Disc Degeneration / therapy*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Microarray Analysis
  • NF-kappa B / metabolism*
  • Signal Transduction / genetics
  • Signal Transduction / physiology
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism

Substances

  • MicroRNAs
  • Mirn141 microRNA, mouse
  • NF-kappa B
  • Sirt1 protein, mouse
  • Sirtuin 1